Pfizer is buying its way back into the obesity-drug game after fighting off a rival bid from Novo Nordisk to buy Metsera, with more money and help from the Trump administration

Pfizer will launch an auction process in November to sell off its consumer healthcare business, unnamed sources told Reuters. Here are four things to know. 1. Pfizer first said it was contemplating strategic options for the unit Oct. 10. 2. Pfizer Consumer ...

Subscribe to The St. Louis American‘s free weekly newsletter for critical stories, community voices, and insights that matter. Sign up Pfizer Consumer Healthcare is voluntarily recall of one lot of its ThermaCare HeatWraps Menstrual product distributed ...

With Pfizer’s final stake sale in the bag, the two Big Pharma companies behind Haleon’s genesis have formally parted ways with the standalone consumer health giant. After charting similar moves throughout 2024, Pfizer on Tuesday unveiled plans to sell ...

Pfizer on Tuesday reported fourth-quarter earnings and revenue that beat estimates as sales of the company's Covid products topped expectations and its broad cost-cutting efforts took hold. The results cap off a critical year for Pfizer, which has been ...

Editor’s Note: This article has been corrected to reflect that the senators asked UpScriptHealth to respond. In August 2024, Pfizer Inc (NYSE:PFE) introduced the PfizerForAll digital platform in collaboration with UpScriptHealth, Alto Pharmacy, and ...

Pfizer's Q3 results are due on Nov. 4, with analysts eyeing $16.6B in sales and EPS of 66 cents as investors weigh the stock's next move.

Pfizer also has set its sights on becoming a giant in oncology, and to support this, completed the acquisition of Seagen in 2023. Two of Seagen's products in the most recent quarter delivered double-digit growth, and Seagen's technology and pipeline offer Pfizer the opportunity to further expand its oncology portfolio.